387 related articles for article (PubMed ID: 29195616)
1. PET/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up.
Karls S; Shah H; Jacene H
Semin Nucl Med; 2018 Jan; 48(1):37-49. PubMed ID: 29195616
[TBL] [Abstract][Full Text] [Related]
2. PET/CT: Clinical role in lymphomas.
Papathanasiou N
Hell J Nucl Med; 2023; 26 Suppl():36-37. PubMed ID: 37658560
[No Abstract] [Full Text] [Related]
3. Staging and response assessment in lymphomas: the new Lugano classification.
Cheson BD
Chin Clin Oncol; 2015 Mar; 4(1):5. PubMed ID: 25841712
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma.
Ulaner GA; Goldman DA; Sauter CS; Migliacci J; Lilienstein J; Gönen M; Schöder H; Moskowitz CH; Zelenetz AD
Radiology; 2015 Nov; 277(2):518-26. PubMed ID: 26035588
[TBL] [Abstract][Full Text] [Related]
5. False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma.
Ulaner GA; Lilienstein J; Gönen M; Maragulia J; Moskowitz CH; Zelenetz AD
J Clin Oncol; 2014 Jan; 32(1):51-6. PubMed ID: 24248697
[TBL] [Abstract][Full Text] [Related]
6. PET-CT in Staging, Response Evaluation, and Surveillance of Lymphoma.
Thanarajasingam G; Bennani-Baiti N; Thompson CA
Curr Treat Options Oncol; 2016 May; 17(5):24. PubMed ID: 27032646
[TBL] [Abstract][Full Text] [Related]
7. FDG-PET/CT in the management of lymphomas: current status and future directions.
El-Galaly TC; Villa D; Gormsen LC; Baech J; Lo A; Cheah CY
J Intern Med; 2018 Oct; 284(4):358-376. PubMed ID: 29989234
[TBL] [Abstract][Full Text] [Related]
8.
Tamayo P; Martín A; Díaz L; Cabrero M; García R; García-Talavera P; Caballero D
Rev Esp Med Nucl Imagen Mol; 2017; 36(5):312-321. PubMed ID: 28483374
[TBL] [Abstract][Full Text] [Related]
9. PET/CT for Staging; Past, Present, and Future.
El-Galaly TC; Gormsen LC; Hutchings M
Semin Nucl Med; 2018 Jan; 48(1):4-16. PubMed ID: 29195617
[TBL] [Abstract][Full Text] [Related]
10. [Update on the use of FDG-PET/CT in malignant lymphoma].
Terauchi T
Rinsho Ketsueki; 2016; 57(10):2008-2012. PubMed ID: 27795508
[TBL] [Abstract][Full Text] [Related]
11. The contribution of metabolic parameters of FDG PET/CT prior and during therapy of adult patients with lymphomas.
Prieto Prieto JC; Vallejo Casas JA; Hatzimichael E; Fotopoulos A; Kiortsis DN; Sioka C
Ann Nucl Med; 2020 Oct; 34(10):707-717. PubMed ID: 32924071
[TBL] [Abstract][Full Text] [Related]
12.
Ruff A; Ballard HJ; Pantel AR; Namoglu EC; Hughes ME; Nasta SD; Chong EA; Bagg A; Ruella M; Farwell MD; Svoboda J; Sellmyer MA
Mol Imaging Biol; 2021 Dec; 23(6):818-826. PubMed ID: 34231105
[TBL] [Abstract][Full Text] [Related]
13. Post-treatment positron emission tomography-computed tomography is highly predictive of outcome in Plasmablastic lymphoma.
Al Tabaa Y; Tchernonog E; Faurie P; Cottereau AS; Monjanel H; Bonnet A; Le Gouill S; Gyan E; Ghesquieres H; Mariano-Goulart D; Cartron G
Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1705-1709. PubMed ID: 29679112
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC).
Fallanca F; Alongi P; Incerti E; Gianolli L; Picchio M; Kayani I; Bomanji J
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1837-48. PubMed ID: 27154522
[TBL] [Abstract][Full Text] [Related]
15. Different predictive values of interim
Kim J; Lee JO; Paik JH; Lee WW; Kim SE; Song YS
Ann Nucl Med; 2017 Jan; 31(1):1-11. PubMed ID: 27627889
[TBL] [Abstract][Full Text] [Related]
16. 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography in primary extranodal lymphomas: treatment response evaluation and prognosis.
Salvatore B; Fonti R; De Renzo A; Pellegrino S; Ferrara IL; Mainolfi CG; Marano L; Selleri C; Pane F; Del Vecchio S; Pace L
Q J Nucl Med Mol Imaging; 2020 Jun; 64(2):219-225. PubMed ID: 29697219
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
Qiao W; Zhao J; Wang C; Wang T; Xing Y
Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
[TBL] [Abstract][Full Text] [Related]
18. Multicenter Comparison of Contrast-Enhanced FDG PET/CT and 64-Slice Multi-Detector-Row CT for Initial Staging and Response Evaluation at the End of Treatment in Patients With Lymphoma.
Gómez León N; Delgado-Bolton RC; Del Campo Del Val L; Cabezas B; Arranz R; García M; Cannata J; González Ortega S; Pérez Sáez MÁ; López-Botet B; Rodríguez-Vigil B; Mateo M; Colletti PM; Rubello D; Carreras JL
Clin Nucl Med; 2017 Aug; 42(8):595-602. PubMed ID: 28604477
[TBL] [Abstract][Full Text] [Related]
19. Whole body magnetic resonance with diffusion weighted sequence with body signal suppression compared to (18)F-FDG PET/CT in newly diagnosed lymphoma.
Ferrari C; Minoia C; Asabella AN; Nicoletti A; Altini C; Antonica F; Ficco M; Guarini A; Maggialetti N; Rubini G
Hell J Nucl Med; 2014; 17 Suppl 1():40-9. PubMed ID: 24392468
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]